Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Atossa Therapeutics Inc (NASDAQ: ATOS) closed at $1.46 down -2.01% from its previous closing price of $1.49. In other words, the price has decreased by -$2.01 from its previous closing price. On the day, 1.45 million shares were traded. ATOS stock price reached its highest trading level at $1.52 during the session, while it also had its lowest trading level at $1.42.
Ratios:
For a deeper understanding of Atossa Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.61 and its Current Ratio is at 17.61. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on January 26, 2018, initiated with a Buy rating and assigned the stock a target price of $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 10 ’24 when Finn Jonathan bought 25,000 shares for $1.77 per share. The transaction valued at 44,250 led to the insider holds 25,000 shares of the business.
WEAVER GREGORY L sold 50,000 shares of ATOS for $32,500 on Nov 15 ’23. The Former EVP, CFO, & Director now owns 55 shares after completing the transaction at $0.65 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATOS now has a Market Capitalization of 183241680 and an Enterprise Value of 94483936.
Stock Price History:
The Beta on a monthly basis for ATOS is 1.23, which has changed by 1.0563381 over the last 52 weeks, in comparison to a change of 0.2704494 over the same period for the S&P500. Over the past 52 weeks, ATOS has reached a high of $2.31, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -5.52%, while the 200-Day Moving Average is calculated to be 45.33%.
Shares Statistics:
For the past three months, ATOS has traded an average of 1.86M shares per day and 1471500 over the past ten days. A total of 125.30M shares are outstanding, with a floating share count of 125.25M. Insiders hold about 0.04% of the company’s shares, while institutions hold 12.98% stake in the company. Shares short for ATOS as of 1714435200 were 11442914 with a Short Ratio of 6.16, compared to 1711584000 on 10563547. Therefore, it implies a Short% of Shares Outstanding of 11442914 and a Short% of Float of 9.13.
Earnings Estimates
The current assessment of Atossa Therapeutics Inc (ATOS) involves the perspectives of 3.0 analysts closely monitoring its market dynamics.On average, analysts expect EPS of -$0.07 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.07, while EPS last year was -$0.05. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.06 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.24 and -$0.31 for the fiscal current year, implying an average EPS of -$0.27. EPS for the following year is -$0.29, with 4.0 analysts recommending between -$0.26 and -$0.35.
